Hepatobiliary Flashcards

1
Q

Fibrolamellar cancer is a variant of HCC, who is it most common in? And how is it treated?

A

Its most common in women and Asian patients. It has a bimodal age distribution and is seen in a lot of younger patients (18-30). It is treated w/surgical resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

After a patient undergoes surgical resection or ablation of HCC, what is the criteria to give adjuvant therapy and what is it?

A

Tumor greater than 5cm, more than 3 tumors, macro or micro vascular invasion, grade 3/4. You give Atezolizumab plus Bevacizumab.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the resection criteria for HCC?

A

Solitary mass w/o vascular invasion, Child Pugh A w/o portal HTN (sometimes mild PHTN is okay), adequate future liver remnant (at least 20% w/o cirrhosis and at least 30-40% with Child Pugh A cirrhosis).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What candidates right away should be considered for transplant?

A

Afp less or equal to 1000, a single lesion of 2 or higher up to 5cm, or 2 or 3 lesions 1-3cm in size. Also no macrovascular disease or extrahepatic dx.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the preferred options for first line tx of advanced/metastatic HCC?

A

Atezolizumab+Bevacizumab or Tremelimumab+Durvalumab (OS benefit only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are other Cat 1 options for first line tx for locally advanced/metastatic HCC?

A

Durvalumab, Lenvatinib, Sorafenib, Tislelizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the options for 2nd line tx for advanced/metastatic HCC?

A

Cabozantinib (Cat 1), Regorafenib (Cat 1), Ramucirumab (For AFP of 400 or more, Cat1), Pembro (can be used for MSI-H or MSI low), Ipi/Nivo, can also do Nivo alone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the indication of Dostarlimab in advanced/metastatic HCC?

A

It is used in 2nd line tx for patients with MSI-H/dMMR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Targeted therapy options in advanced/metastatic disease.

A

Repotrectinib-first line, Cat 2B
Selpercatinib-2nd line, Cat 2B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

For gall bladder cancers that are T1b, T2, T3 that are incidentally found on cholecystectomy what additional management is needed?

A

They need re-resection to include lymphadenectomy and bile duct resection to achieve a RO resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Neoadjuvant therapy for gall bladder cancer hasn’t been studied, but NCCN says you can consider it and use the regimens you use in the metastatic setting. Given for 2-6 months.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the survival benefit with adjuvant chemo or chemo/RT in gall bladder cancer? What is the Cat 1 rec for this and who do you especially give this to? What can you use for chemo/RT?

A

There are data that show a survival benefit with either modality. Give in those w/nodal dx. Give up to 6 months. Chemo-Capecitabine (showed OS benefit). Other options-Gem w/Cisplatin or Capecitabine. 5-FU and Capecitabine can be used with RT.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the first line tx for advanced/metastatic Gall Bladder cancer?

A

Gem w/Cisplatin and Durvalumab (Cat 1)
Pembro w/Gem and Cis (Cat 1). You can also do Gem/Cis alone (Cat 1).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the preferred 2nd line agent for Gall Bladder cancer that is advanced or metastatic?

A

FOLFOX is the preferred option. You can also do FOLFIRI and NALIRI (Cat 2B) (liposomal irinotecan, 5-FU, Leucovorin).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Don’t forget that you have targeted therapy as options for metastatic Gall Bladder Cancer

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pay attention to the targeted therapy options that can be used in first line tx for advanced/metastatic biliary tract cancer?

A

NTRK-entrectinib, repotrectinib, larotrectinib
MSI-H/dMMR-Pembro
TMB-H-Ipi/Nivo (Cat 2B)
RET-Selpercatinib or Pralsetinib both Cat 2B

17
Q

What are the targeted therapy options you can you only use for biliary tract cancer in the 2nd line setting?

A

Remember that you have the options that you use in the front line. BRAF-Dabrafenib/Trametinib. CCA w/FGFR2 fusion or rearrangement-Pemigatinib, Futibatinib. CCA w/IDH-1: Ivosedinib. HER2: Trastuzuamb w/Pertuzumab or Tucatinib or TDX1 (IHC 3+). KRAS G12C-Adagrasib.

18
Q

Recognize the immunotherapy combinations in 2nd line biliary tract cancer?

A

MSI-H/dMMR: Pembro or Dostarlimab
TMB-H: Pembro or Ipi/Nivo

19
Q

What are some side effects seen with Pemigatinib?

A

retinal pigment epithelial detachment, hyperphosphatemia, calcinosis/calciphylaxis, hand/foot syndrome, alopecia, diarrhea, arthralgia.